8-K: APUS Battles Hostile Takeover Attempt by Inscobee

Apimeds Pharmaceuticals US, Inc. announced a material breach of its merger agreement by Inscobee Inc., which attempted a hostile takeover of its Board of Directors.

Summary

• Inscobee Inc. and its subsidiary Apimeds Inc. (together, Inscobee) filed an Amendment No. 2 to Schedule 13D on March 20, 2026, purporting to effect a hostile takeover of Apimeds Pharmaceuticals US, Inc.'s (APUS) Board of Directors by written consent.
• Inscobee claims to have removed all four sitting directors of APUS and installed three hand-picked replacements without company authorization or notice.
• APUS considers these actions void and a direct violation of the Stockholder Support and Lock-Up Agreement signed by Inscobee on December 1, 2025.
• Under the Support Agreement, Inscobee granted APUS an irrevocable proxy over all of its shares and waived rights that would impede the merger.
• Inscobee used 6,416,365 shares, which were subject to the irrevocable proxy, to execute the purported written consent without APUS's authorization.
• APUS states that without these shares, the consent falls short of the majority required under Delaware law and is invalid.
• The purported actions also claimed to remove Dr. Vin Menon as CEO and Mr. Erick Frim as CFO, and to amend the company's bylaws, all of which APUS deems invalid.
• The alleged new directors approved expansion into new business initiatives and operations, including memoranda of understanding with joint ventures with Assemble Corporation, Hilluck Co. Ltd., and LK Ventures Co., Ltd., without the authorization of the duly appointed Board or officers.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the severe corporate governance dispute, material breach of contract, and the necessity for extensive legal action, which introduces significant uncertainty and potential disruption to the company's strategic objectives and operations.

Positives

• APUS is taking swift and decisive legal action by preparing to file an emergency action in the Delaware Court of Chancery to declare Inscobee's actions void and preserve the existing Board and management.
• APUS has engaged legal counsel in Seoul, Korea, to investigate and pursue all available remedies against Inscobee under Korean law, demonstrating a comprehensive legal strategy.
• The company has notified its transfer agent and NYSE American of the dispute, ensuring that corporate records and market operations are not improperly altered based on the purported changes.
• APUS remains committed to completing the Preferred Stock conversion and all transactions contemplated by the Merger Agreement in an expeditious and lawful manner, signaling stability in its strategic objectives.

Negatives

• Inscobee's actions constitute a material breach of the Stockholder Support and Lock-Up Agreement, undermining a critical contractual framework for the merger.
• The purported hostile takeover attempt creates significant corporate governance instability and uncertainty regarding the company's leadership and strategic direction.
• The dispute necessitates costly and time-consuming legal proceedings in both the United States and Korea, diverting resources and attention from core business operations.
• The validity of the company's Board of Directors and executive management is under active dispute, potentially impacting operational continuity and decision-making.
• The purported new directors have already approved new business initiatives and joint ventures without the authorization of the duly appointed Board, creating potential liabilities and confusion.

Risks

• The ongoing legal dispute could significantly impede, disrupt, or adversely affect the consummation of the merger between APUS and MindWave Innovations Inc.
• APUS faces substantial legal costs and expenses associated with litigation in both Delaware and Korea to defend its position and enforce contractual rights.
• The uncertainty surrounding corporate control and management could negatively impact investor confidence, operational stability, and relationships with other stakeholders.
• There is a risk that third parties might rely on or act based on the purported Stockholder Consent, leading to further complications and potential invalid actions.
• The dispute could lead to prolonged instability, potentially delaying strategic initiatives and the company's ability to execute its business plan effectively.

Future Outlook

APUS remains committed to completing the Preferred Stock conversion and all transactions contemplated by the Merger Agreement in an expeditious and lawful manner. The company intends to pursue every available legal remedy in both the United States and Korea to hold Inscobee accountable and ensure contractual commitments are honored.

Management Comments

• The Company considers Inscobee's actions void and of no legal effect.
• Inscobee's actions represent a calculated breach of the contractual framework governing the merger between APUS and MindWave.
• Without those shares (6,416,365 shares subject to irrevocable proxy), the consent falls far short of the majority required under Delaware law and is invalid on its face.
• The Company will defend the interests of all of its shareholders, including the legacy APUS shareholders whose investments Inscobee have placed at risk through this unlawful action.
• The Company intends to pursue every available legal remedy, in both the United States and Korea, to hold Inscobee accountable for the damage their actions have caused and to ensure that binding contractual commitments are honored.
• The Company's position is that no departure of any director or officer of the Company has occurred. Dr. Vin Menon continues to serve as the Company's Chief Executive Officer, Mr. Erick Frim continues to serve as the Company's Chief Financial Officer, and each of Ms. Kogan, Mr. Koo, Ms. O'Donnell, and Dr. Weintraub continues to serve as a member of the Board.

Industry Context

StockSavvy.ai notes that this situation highlights the critical importance of robust corporate governance and the enforceability of shareholder agreements in M&A transactions. Such disputes, while not directly tied to broader therapeutic industry trends, can significantly disrupt a company's strategic direction and operational focus, potentially deterring future partnerships or investments. The legal battle over board control and contractual breaches is a classic example of shareholder activism turning hostile, underscoring the need for clear legal frameworks and proactive defense mechanisms.

Management Changes

Corporate Governance

Legal Proceedings

• APUS will file an emergency action in the Delaware Court of Chancery pursuant to 8 Del. C. § 225 seeking a declaration that the purported written consent is void, that the existing Board of Directors remains validly seated, and that the purported new directors hold no valid office.
• The Delaware filing will include a motion for a Temporary Restraining Order to preserve the status quo and prevent the purported directors from taking any corporate action pending judicial resolution.
• APUS has engaged legal counsel in Seoul, Korea, to investigate and pursue all available remedies against Inscobee under Korean law, including in connection with Inscobee's conduct toward its own shareholders and its obligations under Korean corporate governance standards.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the company's leadership and strategic direction, potentially impacting share value and future investment decisions.
• The dispute could lead to prolonged legal battles and associated costs, which may ultimately be borne by shareholders.
• The validity of the merger agreement and its contemplated transactions is at risk, affecting the expected benefits for all parties involved.
• Employees may experience uncertainty regarding management stability and the company's future, potentially impacting morale and retention.
• Customers and suppliers may face confusion or hesitation in dealings with the company due to the disputed corporate control.

Next Steps

• APUS and MindWave will file an emergency action in the Delaware Court of Chancery pursuant to 8 Del. C. § 225.
• The emergency action will seek a declaration that the purported written consent is void, that the existing Board of Directors remains validly seated, and that the purported new directors hold no valid office.
• The filing will include a motion for a Temporary Restraining Order to preserve the status quo and prevent the purported directors from taking any corporate action.
• APUS has engaged legal counsel in Seoul, Korea, to investigate and pursue all available remedies against Inscobee under Korean law.
• APUS has notified its transfer agent that the Board composition is under active dispute and that no changes to stock records or corporate records should be made based on instructions from the purported new directors.
• APUS has notified NYSE American of the dispute.

Key Dates

Recommendation

A 'hold' recommendation is appropriate given the significant corporate governance dispute and ongoing legal battle. While APUS is taking strong legal action to defend its position, the outcome is uncertain and could lead to prolonged instability, legal costs, and potential disruption to the merger. Investors should monitor the legal proceedings closely, as the resolution of this dispute will be critical to the company's future stability and strategic execution. The current situation introduces substantial risk, making a 'buy' premature, but the company's proactive defense prevents an immediate 'sell' recommendation without further clarity on the legal and operational impact.

Keywords

Hostile Takeover, Merger Agreement Breach, Corporate Governance Dispute, SEC Filing, Delaware Court of Chancery, Irrevocable Proxy, Stockholder Support Agreement, APUS, Inscobee, MindWave Innovations, Legal Action, NYSE American